AGC Biologics’ has purchased a state-of-the-art commercial biopharmaceutical facility in Boulder, CO. The facility, formerly owned by AstraZeneca, will provide AGC Biologics with additional commercial-scale manufacturing capacity for its biopharmaceutical CDMO business when it enters operation in April 2021, more than 18 months sooner than a new-build facility.   AGC Biologics worked with International Process Plants (IPP), a global buyer and seller of pharmaceutical and biopharmaceutical ...